+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying the effects of PIPE-791 in adults aged 40 years and older with Idiopathic Pulmonary Fibrosis IPF, a lung disease characterized by progressive scarring. This Phase 2, randomized, double-blind, placebo-controlled global study aims to evaluate the efficacy, safety, tolerability, and how the body processes PIPE-791 in participants who may or may not be receiving other approved IPF treatments. The study is sponsored by Contineum Therapeutics and will enroll approximately 324 participants. Participants will be assigned to one of three groups two different daily oral doses of PIPE-791 or a placebo. The treatment period lasts 26 weeks. The full study duration extends up to 36 weeks, including screening before treatment and follow-up after treatment ends. Participants receive their assigned tablets daily during the treatment phase. Throughout the study, participants will undergo lung function tests such as forced vital capacity FVC, high-resolution CT scans to assess lung fibrosis, and safety monitoring for any side effects or adverse events. Researchers will track changes in lung function and overall health from the start of treatment to week 26, with additional safety follow-up until week 30. The study involves regular visits for assessments, and participant involvement may last up to 36 weeks in total.

Age: 40Years +All GendersPhase 2
107 locations